UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

The New England journal of medicine, 2017-09, Vol.377 (12), p.1119-1131

2017

Volltextzugriff (PDF)

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

The New England journal of medicine, 2019-10, Vol.381 (17), p.1609-1620

2019

Volltextzugriff (PDF)

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

The New England journal of medicine, 2015-05, Vol.372 (19), p.1791-1800

2015

Volltextzugriff (PDF)

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

The New England journal of medicine, 2021-11, Vol.385 (20), p.1845-1855

2021

Volltextzugriff (PDF)

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

The New England journal of medicine, 2014-09, Vol.371 (11), p.993-1004

2014

Volltextzugriff (PDF)

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

The New England journal of medicine, 2017-10, Vol.377 (16), p.1513-1524

2017

Volltextzugriff (PDF)

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2018-01, Vol.391 (10117), p.219-229

2018

Volltextzugriff (PDF)

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

The New England journal of medicine, 2013-10, Vol.369 (14), p.1327-1335

2013

Volltextzugriff (PDF)

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

The New England journal of medicine, 2017-05, Vol.376 (20), p.1933-1942

2017

Volltextzugriff (PDF)

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

The Lancet (British edition), 2015-05, Vol.385 (9982), p.2067-2076

2015

Volltextzugriff (PDF)

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

The Lancet (British edition), 2018-01, Vol.391 (10117), p.205-218

2018

Volltextzugriff (PDF)

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)

Circulation. Arrhythmia and electrophysiology, 2017-01, Vol.10 (1), p.e004267-e004267

2017

Volltextzugriff (PDF)

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

Stroke (1970), 2016-08, Vol.47 (8), p.2075-2082

2016

Volltextzugriff (PDF)

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Diabetologia, 2011-03, Vol.54 (3), p.487-495

2011

Volltextzugriff (PDF)

Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48

Clinical cardiology (Mahwah, N.J.), 2016-06, Vol.39 (6), p.345-346

2016

Volltextzugriff (PDF)

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

Diabetes care, 2016-07, Vol.39 (7), p.1267-1273

2016

Volltextzugriff (PDF)

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Stroke (1970), 2014-08, Vol.45 (8), p.2372-2378

2014

Volltextzugriff (PDF)

Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease

Journal of hypertension, 2014-12, Vol.32 (12), p.2479-2487

2014

Volltextzugriff (PDF)

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

Hypertension (Dallas, Tex. 1979), 2016-09, Vol.68 (3), p.606-613

2016

Volltextzugriff (PDF)

Prevalence of Heart Failure With Preserved Ejection Fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER Study (Identification of Patients With Heart Failure and PREserved Systolic Function: An Epidemiological Regional Study)

The American journal of cardiology, 2011-11, Vol.108 (9), p.1289-1296

2011

Volltextzugriff (PDF)

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial

JAMA cardiology, 2021-11, Vol.6 (11), p.1298

2021

Volltextzugriff (PDF)

Gabapentin-induced central hypoventilation

Medicina clínica, 2007-04, Vol.128 (13), p.519

2007

Volltextzugriff (PDF)

Lithotripsy with the Alexandrite Laser: Our Initial 100 Clinical Cases(1)

European urology, 1991-01, Vol.20 (4), p.269-271

1991

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Aktive Filter

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(37)

Sprache

Englisch
(24)
Spanisch
(13)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial

Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48)

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48

Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial

Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin: Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

Reversibility of left ventricular mechanical dysfunction in patients with hypertensive heart disease

Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin

Prevalence of Heart Failure With Preserved Ejection Fraction in Latin American, Middle Eastern, and North African Regions in the I PREFER Study (Identification of Patients With Heart Failure and PREserved Systolic Function: An Epidemiological Regional Study)

Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial

Gabapentin-induced central hypoventilation

Lithotripsy with the Alexandrite Laser: Our Initial 100 Clinical Cases(1)

Aktive Filter

Suchergebnisse filtern